Sezer, SevilayUçar, FatmaUlusoy, Ersin KasımErdoğan, SerpilBilen, ŞuleZüngün, CevdetUysal, SemaErdemli, Hacı Kemal2019-05-132019-05-132014Sezer, S., Uçar, F., Ulusoy, E. K., Erdoğan, S., Bilen, Ş., Züngün, C., Uysal, S., Erdemli, H. K. (2014). Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers?. Turkish Journal of Medical Sciences, 44(1), 16-23.1300-0144https://doi.org/10.3906/sag-1211-90https://hdl.handle.net/11491/1329Aim: Inflammation plays an important role in acute ischemic stroke. In this study we aimed to investigate the relationship between acute ischemic stroke and serum amyloid A, fetuin-A, and pentraxin-3 which are inflammation markers. Materials and methods: We enrolled 52 patients with acute ischemic stroke and 30 sex-matched control subjects in the study. The patients were followed for 3 months. We evaluated the common risk factors, laboratory variables, and neurological examination of stroke patients according to prognosis scales. Results: The median serum amyloid A, fetuin-A, and pentraxin-3 levels in the stroke patients were higher than in control subjects (respectively, P = 0.000, P = 0.002, and P = 0.037). National Institutes of Health Stroke Scale scores, glucose, C-reactive protein, fibrinogen, and white blood cell count showed differences within the group in terms of the serum amyloid A tertiles statistically. Conclusion: Pentraxin-3, fetuin-A, and serum amyloid A all arise together as novel prognostic factors in a group of patients with ischemic stroke. Relationships between higher levels of inflammation markers, especially serum amyloid A, and the severity of acute ischemic stroke were shown. © TÜBİTAK.eninfo:eu-repo/semantics/openAccessAcute Ischemic StrokeFetuin-APentraxin-3Serum Amyloid AArticle441162310.3906/sag-1211-90N/AQ1